Clinical trial

Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs

NCT00819741

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-02-01

PhasePHASE4

Study timeline

Study start (unknown)2009-02-01Date precision: month

Registry last updated2017-02-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetesunresolved

Diabetes Mellitus, Type 2unresolved

Interventions

repaglinideDRUG · verified · RxNorm: repaglinide

metforminDRUG · verified · RxNorm: metformin

repaglinideDRUG · verified · RxNorm: repaglinide

Sponsors & collaborators

Novo Nordisk A/Slead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China5 NanjingJiangsu, China3 ShanghaiChina1 HangzhouZhejiang, China1 HangzhouChina1 FuzhouFujian, China1 NanchangJiangxi, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00819741 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.